Filing Details
- Accession Number:
- 0001035443-22-000176
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-06-29 16:37:37
- Reporting Period:
- 2022-06-27
- Accepted Time:
- 2022-06-29 16:37:37
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1697532 | Applied Therapeutics Inc. | APLT | Real Estate Investment Trusts (6798) | MD |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1035443 | Alexandria Real Estate Equities, Inc. | 26 North Euclid Avenue Pasadena CA 91101 | No | No | Yes | No | |
1722024 | Alexandria Venture Investments, Llc | 26 North Euclid Avenue Pasadena CA 91101 | No | No | Yes | No | |
1776437 | Alexandria Equities No. 7, Llc | 26 North Euclid Avenue Pasadena CA 91101 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-06-27 | 1,435,000 | $1.00 | 2,378,977 | No | 4 | P | Indirect | By subsidiary |
Common Stock | Acquisiton | 2022-06-27 | 2,065,000 | $1.00 | 4,555,077 | No | 4 | P | Indirect | By subsidiary |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | By subsidiary |
No | 4 | P | Indirect | By subsidiary |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Pre-Funded Warrant | Acquisiton | 2022-06-27 | 615,000 | $1.00 | 615,000 | $0.00 |
Common Stock | Pre-Funded Warrant | Acquisiton | 2022-06-27 | 885,000 | $1.00 | 885,000 | $0.00 |
Common Stock | Common Stock Warrant | Acquisiton | 2022-06-27 | 2,050,000 | $0.00 | 2,050,000 | $1.00 |
Common Stock | Common Stock Warrant | Acquisiton | 2022-06-27 | 2,950,000 | $0.00 | 2,950,000 | $1.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
615,000 | No | 4 | P | Indirect | ||
885,000 | No | 4 | P | Indirect | ||
2,050,000 | No | 4 | P | Indirect | ||
2,950,000 | No | 4 | P | Indirect |
Footnotes
- These securities were purchased at a combined public offering price of $1.00 per share of Common Stock and associated Common Stock Warrant (or, in the case of the Pre-Funded Warrants, $0.9999 per Pre-Funded Warrant and associated Common Stock Warrant).
- These securities are held directly by Alexandria Equities No. 7, LLC ("AE7"), a wholly owned subsidiary of Alexandria Real Estate Equities, Inc.
- These securities are held directly by Alexandria Venture Investments, LLC ("AVI"), an affiliate of AE7 and another wholly owned subsidiary of Alexandria Real Estate Equities, Inc.
- The Pre-Funded Warrants are exercisable immediately and will expire five years from the date of issuance. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise.
- The Common Stock Warrants are exercisable immediately and will expire five years from the date of issuance. The Common Stock Warrants may not be exercised to the extent such exercise would cause the holder (together with its affiliates, any other persons acting as a group together with the holder or any of the holder's affiliates, and any other persons whose beneficial ownership of the Issuer's common stock would or could be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended) to beneficially own more than 19.99% of the Issuer's common stock outstanding immediately after giving effect to such exercise.